Soleno Therapeutics, Inc. (SLNO)Healthcare | Biotechnology | Redwood City, United States | NasdaqCM
52.69 USD
+0.12
(0.219%)
⇧
(April 17, 2026, 2:26 p.m.
EDT)
Short-term: ★★★☆☆ | Long-term: ★★☆☆☆ | Dividends: ☆☆☆☆☆ |
Hot Take | April 11, 2026, 2:49 p.m. EDT
SLNO is currently experiencing a mix of positive and negative factors. The recent news about a potential acquisition by Neurocrine and a significant price surge could indicate strong momentum, but the presence of multiple lawsuits and a high beta suggest increased risk. The short-term price forecast shows a slight decline, but the recent price action and options activity suggest that there might be opportunities for short-term traders. However, for long-term investors, the high overall risk and lack of consistent dividends make it a less attractive option. The stock is currently volatile and should be approached with caution. |
| Model | MAE |
|---|---|
| MSTL ✓ | 0.140886 |
| AutoETS | 0.143067 |
| AutoARIMA | 0.143070 |
| AutoTheta | 0.154379 |
Forecast horizon: 45 days | Selected: MSTL
| Forecast Reliability | |
|---|---|
| Score | 42% |
| H-stat | 14.65 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.760 |
| Excess Kurtosis | 0.15 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 11.675 |
| Revenue per Share | 3.747 |
| Market Cap | 2,724,770,816 |
| Trailing P/E | 135.09 |
| Forward P/E | -23.21 |
| Beta | -2.81 |
| Profit Margins | 10.97% |
| Website | https://soleno.life |
As of April 11, 2026, 2:49 p.m. EDT: The options activity shows mixed signals. The calls and puts have varying levels of open interest and volume, with some strikes indicating potential for both bullish and bearish movements. The high IV on certain strikes suggests uncertainty or speculation about future price movements. The ATM anchors for calls and puts indicate that traders are closely watching the current price level. Overall, the options data suggests a cautious outlook with potential for volatility.
| Attribute | Value |
|---|---|
| 52 Week Change | -0.23734224 |
| Address1 | 100 Marine Parkway |
| Address2 | Suite 400 |
| All Time High | 742.5 |
| All Time Low | 0.85 |
| Ask | 67.34 |
| Ask Size | 1 |
| Audit Risk | 10 |
| Average Analyst Rating | 2.8 - Hold |
| Average Daily Volume10 Day | 11,996,400 |
| Average Daily Volume3 Month | 3,295,600 |
| Average Volume | 3,295,600 |
| Average Volume10Days | 11,996,400 |
| Beta | -2.805 |
| Bid | 52.63 |
| Bid Size | 1 |
| Board Risk | 7 |
| Book Value | 8.609 |
| City | Redwood City |
| Compensation As Of Epoch Date | 1,735,603,200 |
| Compensation Risk | 10 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 52.685 |
| Current Ratio | 5.799 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,774,915,200 |
| Day High | 52.69 |
| Day Low | 52.6 |
| Debt To Equity | 11.675 |
| Display Name | Soleno Therapeutics |
| Dividend Date | 1,507,248,000 |
| Earnings Call Timestamp End | 1,772,055,000 |
| Earnings Call Timestamp Start | 1,772,055,000 |
| Earnings Timestamp | 1,772,053,200 |
| Earnings Timestamp End | 1,778,097,600 |
| Earnings Timestamp Start | 1,778,097,600 |
| Ebitda | 16,967,000 |
| Ebitda Margins | 0.08911 |
| Enterprise To Ebitda | 145.045 |
| Enterprise To Revenue | 12.925 |
| Enterprise Value | 2,460,974,848 |
| Eps Forward | -2.27 |
| Eps Trailing Twelve Months | 0.39 |
| Esg Populated | 0 |
| Exchange | NCM |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fax | 650 213 8383 |
| Fifty Day Average | 39.8613 |
| Fifty Day Average Change | 12.8237 |
| Fifty Day Average Change Percent | 0.32170802 |
| Fifty Two Week Change Percent | -23.734224 |
| Fifty Two Week High | 90.32 |
| Fifty Two Week High Change | -37.635 |
| Fifty Two Week High Change Percent | -0.4166851 |
| Fifty Two Week Low | 29.43 |
| Fifty Two Week Low Change | 23.255001 |
| Fifty Two Week Low Change Percent | 0.7901801 |
| Fifty Two Week Range | 29.43 - 90.32 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,415,889,000,000 |
| Float Shares | 47,898,652 |
| Forward Eps | -2.27 |
| Forward P E | -23.209251 |
| Free Cashflow | 48,272,248 |
| Full Exchange Name | NasdaqCM |
| Full Time Employees | 182 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,775,001,600 |
| Gross Margins | 0.98582 |
| Gross Profits | 187,704,992 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.01735 |
| Held Percent Institutions | 1.29336 |
| Implied Shares Outstanding | 51,718,149 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Last Split Date | 1,661,472,000 |
| Last Split Factor | 1:15 |
| Long Business Summary | Soleno Therapeutics, Inc., biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is VYKAT XR, an extended-release tablets for the treatment of Prader-Willi Syndrome. The company was formerly known as Capnia, Inc. and changed its name to Soleno Therapeutics, Inc. in May 2017. Soleno Therapeutics, Inc. was incorporated in 1999 and is headquartered in Redwood City, California. |
| Long Name | Soleno Therapeutics, Inc. |
| Market | us_market |
| Market Cap | 2,724,770,816 |
| Market State | REGULAR |
| Max Age | 86,400 |
| Message Board Id | finmb_2520553 |
| Most Recent Quarter | 1,767,139,200 |
| Net Income To Common | 20,475,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 2,719,598,865 |
| Number Of Analyst Opinions | 8 |
| Open | 52.615 |
| Operating Cashflow | 46,798,000 |
| Operating Margins | 0.44076002 |
| Overall Risk | 10 |
| Payout Ratio | 0.0 |
| Phone | 650 213 8444 |
| Previous Close | 52.57 |
| Price Hint | 2 |
| Price To Book | 6.1197586 |
| Price To Sales Trailing12 Months | 14.310396 |
| Profit Margins | 0.10971 |
| Quick Ratio | 5.438 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | hold |
| Recommendation Mean | 2.81818 |
| Region | US |
| Regular Market Change | 0.11500168 |
| Regular Market Change Percent | 0.21875913 |
| Regular Market Day High | 52.69 |
| Regular Market Day Low | 52.6 |
| Regular Market Day Range | 52.6 - 52.69 |
| Regular Market Open | 52.615 |
| Regular Market Previous Close | 52.57 |
| Regular Market Price | 52.685 |
| Regular Market Time | 1,776,450,394 |
| Regular Market Volume | 2,534,246 |
| Return On Assets | 0.02088 |
| Return On Equity | 0.060100004 |
| Revenue Per Share | 3.747 |
| Sand P52 Week Change | 0.36506534 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 8 |
| Shares Outstanding | 51,718,149 |
| Shares Percent Shares Out | 0.1634 |
| Shares Short | 8,451,042 |
| Shares Short Previous Month Date | 1,772,150,400 |
| Shares Short Prior Month | 8,870,870 |
| Short Name | Soleno Therapeutics, Inc. |
| Short Percent Of Float | 0.1873 |
| Short Ratio | 5.1 |
| Source Interval | 15 |
| State | CA |
| Symbol | SLNO |
| Target High Price | 110.0 |
| Target Low Price | 53.0 |
| Target Mean Price | 60.125 |
| Target Median Price | 53.0 |
| Total Cash | 305,472,000 |
| Total Cash Per Share | 5.917 |
| Total Debt | 52,553,000 |
| Total Revenue | 190,404,992 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | 0.39 |
| Trailing P E | 135.08975 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 55.97385 |
| Two Hundred Day Average Change | -3.2888489 |
| Two Hundred Day Average Change Percent | -0.05875688 |
| Type Disp | Equity |
| Volume | 2,534,246 |
| Website | https://soleno.life |
| Zip | 94,065 |